Artivion price target raised to $40 from $32 at Oppenheimer

Oppenheimer raised the firm’s price target on Artivion (AORT) to $40 from $32 and keeps an Outperform rating on the shares following quarterly results. The firm notes the company received FDA IDE approval to begin their ArcevoLSA pivotal trial, initiating enrollment before year-end. The company raised FY25 revenue guidance, now $435M-$443M from $423M-$435M vs. its/consensus $430M/$427M estimates, and management remains confident about double-digit top-line growth and growing the bottom line over 2-times that.